Investor Relations

BioSynthema Inc. is a privately held biotechnology company.  The company carries out early stage discovery research, in addition to late stage development of promising lead compounds.  Our most advanced product is a therapeutic agent for treatment of neuroendocine tumors, which has been evaluated in clinical studies at the Erasmus MC since 2001.  BioSynthema expect to file an IND for treatment of neuroendocrine tumors in 2008.